Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin

Pirfenidone, an antifibrotic drug, has antitumor potential against different types of cancers. Our work explored whether pirfenidone sensitizes non-small cell lung cancer (NSCLC) cell lines to chemotherapeutic treatments. The cytotoxic effect of paclitaxel in combination with pirfenidone against three NSCLC cell lines (A549, NCI-H322 and NCI-H460) was evaluated using the sulforhodamine B assay. The effects of this combination on cell viability (trypan blue exclusion assay), proliferation (BrdU incorporation assay), cell cycle (flow cytometry following PI staining) and cell death (Annexin V-FITC detection assay and Western blot) were analyzed on the most sensitive cell line (NCI-H460). The cytotoxic effect of this drug combination was also evaluated against two non-tumorigenic cell lines (MCF-10A and MCF-12A). Finally, the ability of pirfenidone to sensitize NCI-H460 cells to a combination of paclitaxel plus carboplatin was assessed. The results demonstrated that pirfenidone sensitized NCI-H460 cells to paclitaxel treatment, reducing cell growth, viability and proliferation, inducing alterations in the cell cycle profile and causing an increase in the % of cell death. Remarkably, this combination did not increase cytotoxicity in non-tumorigenic cells. Importantly, pirfenidone also sensitized NCI-H460 cells to paclitaxel plus carboplatin. This work highlights the possibility of repurposing pirfenidone in combination with chemotherapy for the treatment of NSCLC.

[1]  C. Mascaux,et al.  Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring , 2021, Cancers.

[2]  C. Boshoff,et al.  Toward personalized treatment approaches for non-small-cell lung cancer , 2021, Nature Medicine.

[3]  H. Bach,et al.  Current and Future Development in Lung Cancer Diagnosis , 2021, International journal of molecular sciences.

[4]  P. Krawczyk,et al.  Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer , 2021, International journal of molecular sciences.

[5]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Vasconcelos,et al.  Synthesis of Novel Methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates and Antitumor Activity Evaluation: Studies In Vitro and In Ovo Grafts of Chick Chorioallantoic Membrane (CAM) with a Triple Negative Breast Cancer Cell Line , 2021, Molecules.

[7]  M. Vasconcelos,et al.  Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma , 2021, Pharmaceuticals.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  C. Schein.  Repurposing approved drugs for cancer therapy , 2021, British medical bulletin.

[10]  J. Thiery,et al.  Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. , 2020, Integrative biology : quantitative biosciences from nano to macro.

[11]  K. Rabe,et al.  The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC , 2020, Frontiers in Oncology.

[12]  Chaofan Liu,et al.  Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice , 2020, Oncoimmunology.

[13]  L. Schaefer,et al.  Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. , 2019, Cellular signalling.

[14]  J. Molina,et al.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.

[15]  M. Vasconcelos,et al.  Eucalyptus globulus Labill. decoction extract inhibits the growth of NCI-H460 cells by increasing the p53 levels and altering the cell cycle profile. , 2019, Food & function.

[16]  Masatoshi Watanabe,et al.  Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest , 2019, Pharmacology.

[17]  E. Sousa,et al.  Synthesis of New Proteomimetic Quinazolinone Alkaloids and Evaluation of Their Neuroprotective and Antitumor Effects , 2019, Molecules.

[18]  K. Iguchi,et al.  Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest , 2019, Journal of clinical medicine.

[19]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[20]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Rönty,et al.  Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo , 2018, Scientific Reports.

[22]  M. Vasconcelos,et al.  Melissa officinalis L. ethanolic extract inhibits the growth of a lung cancer cell line by interfering with the cell cycle and inducing apoptosis. , 2018, Food & function.

[23]  M. Vasconcelos,et al.  Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors , 2018, Molecules.

[24]  S. Papapetropoulos,et al.  Drug repurposing from the perspective of pharmaceutical companies , 2018, British journal of pharmacology.

[25]  Shuai Zhang,et al.  Pirfenidone Inhibits Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[26]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[27]  K. Tatsumi,et al.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. , 2017, Oncology letters.

[28]  M. Okumura,et al.  Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. , 2017, Lung cancer.

[29]  P. Papageorgis,et al.  Pirfenidone normalizes the tumor microenvironment to improve chemotherapy , 2017, Oncotarget.

[30]  Nicola Nosengo.  Can you teach old drugs new tricks? , 2016, Nature.

[31]  S. Antonia,et al.  The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts , 2016, BMC Cancer.

[32]  Hassan Lemjabbar-Alaoui,et al.  Lung cancer: Biology and treatment options. , 2015, Biochimica et biophysica acta.

[33]  A. Mantel‐Teeuwisse,et al.  Drug repositioning and repurposing: terminology and definitions in literature. , 2015, Drug discovery today.

[34]  Hae-June Lee,et al.  Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy. , 2015, Biochemical and biophysical research communications.

[35]  Francesco Petrella,et al.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[36]  M. Kris,et al.  Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. , 2015, The Cochrane database of systematic reviews.

[37]  Sarah Burdett,et al.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.

[38]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[39]  K. Ohuchida,et al.  Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. , 2013, Cancer research.

[40]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[41]  M. Weller,et al.  Pirfenidone inhibits TGF-β expression in malignant glioma cells , 2007 .

[42]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[43]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[44]  A. Gemma,et al.  Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. , 2018, Respiratory investigation.

[45]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[46]  M. Weller,et al.  Pirfenidone inhibits TGF-beta expression in malignant glioma cells. , 2007, Biochemical and biophysical research communications.